Milestone Pharmaceuticals (MIST) Expected to Announce Quarterly Earnings on Thursday

Milestone Pharmaceuticals (NASDAQ:MIST) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $1.65 on Thursday. The stock has a market cap of $140.53 million, a P/E ratio of -2.01 and a beta of 0.48. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $3.06. The stock has a 50 day moving average of $1.89 and a 200 day moving average of $2.00. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74.

Insider Buying and Selling at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, insider Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $124,273.12. Following the transaction, the insider directly owned 196,486 shares of the company’s stock, valued at $455,847.52. The trade was a 21.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph Oliveto sold 34,523 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the completion of the transaction, the chief executive officer directly owned 482,744 shares in the company, valued at $931,695.92. The trade was a 6.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 416,327 shares of company stock worth $935,458 in the last 90 days. 19.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Creative Planning increased its position in shares of Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James Financial Inc. grew its position in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after acquiring an additional 10,000 shares during the last quarter. UBS Group AG grew its position in shares of Milestone Pharmaceuticals by 23.2% during the third quarter. UBS Group AG now owns 397,534 shares of the company’s stock worth $795,000 after acquiring an additional 74,886 shares during the last quarter. Pathstone Holdings LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $2,000,000. Finally, Two Sigma Investments LP purchased a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at $1,333,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on MIST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Wells Fargo & Company lifted their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $8.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.